HongRi pharmaceutical industry builds the industrialization base of traditional Chinese Medicine

Recently, HongRi pharmaceutical announced that Beijing kangrentang, a wholly-owned subsidiary, signed an agreement with 14 natural persons, including Yao Xiaoqing, chairman of the company, to jointly invest 150 million yuan to set up Tianjin hongrikangrentang Pharmaceutical Co., Ltd in Wuqing Development Zone, Tianjin, and to build a comprehensive production base for industrialization of traditional Chinese medicine with hongrikangrentang as the main body It is reported that the project will purchase 300 mu land in Wuqing Development Zone, carry out the construction of basic factory buildings, complete the transformation of production environment according to the requirements of the new GMP, purchase advanced automatic production equipment, and realize the large-scale and modern production of traditional Chinese medicine series products After the completion of the project, the company plans to produce and process about 3000 tons of Chinese herbal pieces and 2500 tons of Chinese herbal granules annually Yesterday, the head of a pharmaceutical enterprise said that in recent years, the domestic market of Chinese herbal pieces is in a high-speed development stage, with an annual growth rate of more than 30%, and in the next five years, the growth momentum will not decrease, and the future development space is huge However, due to policy reasons, only five enterprises in China, including HongRi pharmaceutical, are qualified for production For these qualified companies, there is no doubt that "sky high let birds fly." After the implementation of Wuqing traditional Chinese medicine product automation base of HongRi pharmaceutical, the production capacity of the company's herbal pieces and granules will be greatly improved, breaking the bottleneck of production capacity and continuously improving the company's profitability Therefore, we are optimistic about the long-term development prospect of the company in the future.